Target-based drug discovery: Is something wrong?

Drug Discovery Today

Volumn 10, Issue 2, 2005, Pages 139-147

  Sams Dodd, Frank ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; LEPTIN; MONOAMINE OXIDASE B INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SMALL INTERFERING RNA; TRICYCLIC ANTIDEPRESSANT AGENT;

ALZHEIMER DISEASE; ARTIFICIAL NEURAL NETWORK; DEPRESSION; DRUG DESIGN; DRUG MANUFACTURE; DRUG MECHANISM; DRUG TARGETING; ELECTROCONVULSIVE THERAPY; GENE CONTROL; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; NONHUMAN; OBESITY; REVIEW; RNA INTERFERENCE; SCHIZOPHRENIA;

ANIMALS; COMPUTATIONAL BIOLOGY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; GENOMICS; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 13844276627     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03316-1     Document Type: Review

References (38)

1. Van den Haak, et al. Industry Success Rates 2004. CMR Report 04-234R. 2004
2. FDA. Innovation and Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. 2004;FDA White Paper
3. Chanda S.K., Caldwell J.S., et al. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov. Today. 8:2003;168-174
4. Drews J., et al. Drug Discovery: a historical perspective. Science. 287:2000;1960-1964
5. Drews J. Strategic trends in the drug industry. Drug Discov. Today. 8:2003;411-420
6. Handen J.S., et al. The industrialization of drug discovery. Drug Discov. Today. 7:2002;83-85
7. Drews J., Ryser S., et al. Innovation deficits in the pharmaceutical industry. Drug Inf. J. 30:1996;97-108
8. Weisbach J.A., Moos W.H., et al. Diagnosing the decline of major pharmaceutical research laboratories; a prescription for drug companies. Drug Dev. Res. 34:1995;243-259
9. Brown D., Superti-Furga G. Rediscovering the sweet spot in drug discovery. Drug Discov. Today. 8:2003;1067-1077
10. Arlington S., et al. Pharma 2010 - The Threshold of Innovation. 2004;IBM Business Consulting Services - Future Series
11. Knowles J., Gromo G. Target selection in drug discovery. Nat. Rev. Drug Discov. 2:2003;63-69
12. Kerns E.H., Di L. Pharmaceutical profiling in drug discovery. Drug Discov. Today. 8:2003;316-323
13. Erickson D. Wanted: drug hunters in vivo. The Business and Medicine Report. 21:2003;45-52
14. Lindsay M.A. Target discovery. Nat. Rev. Drug Discov. 2:2003;831-838
15. Drews J. Genomic sciences and the medicines of tomorrow. Nat. Biotechnol. 14:1996;1517-1518
16. Murcko M., Caron P. Transforming the genome to drug discovery. Drug Discov. Today. 7:2002;583-584
17. Drews J. Drug discovery today - and tomorrow. Drug Discov. Today. 5:2000;2-4
18. Thompson J.D. Application of antisense and siRNAs during preclinical development. Drug Discov. Today. 7:2002;912-917
19. Rydling A.D.S., et al. Conditional transgenic technologies. J. Endocrinol. 171:2001;1-14
20. Tenenbaum L., et al. Recombinant AAV-mediated gene delivery to the central nervous system. J. Gene Med. 6:2004;S212-S222
21. Bäckman C., et al. Short interfering RNAs (siRNAs) for reducing dopaminergic phenotypic markers. J. Neurosci. Methods. 131:2003;51-56
22. Xia H., et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10:2004;816-820
23. Dorn G., et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32:2004;e49
24. Legos J.J., et al. Pharmacological interventions for stroke: failures and futures. Expert Opin. Investig. Drugs. 11:2002;603-614
25. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 30:1999;2752-2758
26. Calkins K., Wess L. Stroke: never say die. BioCentury. 11:2003;A1-A7
27. Szymkowski D.E. Too many targets, not enough target validation. Drug Discov. Today. 6:2001;398-399
28. Peakman T., et al. Delivering the power of discovery in large pharmaceutical organisations. Drug Discov. Today. 8:2003;203-211
29. Johnson G., Scholes K. Exploring Corporate Strategy. 6th edn :2001;Prentice Hall
30. Stacy R.D. Strategic Management and Organisational Dynamics: The Challenge of Complexity. 2002;Prentice Hall
31. Yanovski S.Z., Yanovski J.A. Obesity. N. Engl. J. Med. 346:2002;591-602
32. Veniant M.M., LeBel C.P. Leptin: from animals to humans. Curr. Pharm. Des. 9:2003;811-818
33. Brunello N., et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur. Neuropsychopharmacol. 12:2002;461-475
34. Duman R.S. Pathophysiology of depression: the concept of synaptic plasticity. Eur. Psychiatry. 17:(Suppl. 3):2002;306-310
35. Duman R.S., et al. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology. 25:2001;836-844
36. Hirsh S.R., Weinberger D.R. Schizophrenia. 1995;Blackwell Science Ltd
37. Boog G. Obstretical complications and subsequent schizophrenia in adolescent and young adult offsprings: is there a relationship? Eur. J. Obstet. Gynecol. Reprod. Biol. 114:2004;130-136
38. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev. Neurosci. 10:1999;59-90